content_top
43 companies, 1 interpreter! Insight, foresight
and recommendation 

Vericel Corporation (VCEL)

14.10
-0.60
(-4.08%)
Sep 11, 4:00PM EDT
content_middle

Vericel Corporation (VCEL) a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions.

VCEL markets three autologous cell therapy products, including Carticel and MACI, which are used for the treatment of cartilage defects in the knee; and Epicel, a permanent skin replacement that is used for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area in the United States.

VCEL also develops ixmyelocel-T, which is in Phase IIb clinical trial, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy.

The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was founded in 1989 and is headquartered in Cambridge, Massachusetts.

Previous Close: 
4.45
Open: 
4.50
Bid: 
4.40
Ask: 
4.50
1yr Target Price: 
6.59
Day's Range: 
4.40 - 4.55
52wk Range: 
3.30 - 14.80
Volume: 
464242
Average Daily Volume: 
476940
Market Capitalization: 
602.44M
Trailing Annual Dividend Yield: 
N/A
Shares Outstanding: 
42.73M
content_right

Pages